Tempest Therapeutics (Tempest Therapeutics) EBIT per Share : $-1.67 (TTM As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Tempest Therapeutics EBIT per Share?

Tempest Therapeutics's EBIT per Share for the three months ended in Mar. 2024 was $-0.34. Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2024 was $-1.67.

During the past 3 years, the average EBIT per Share Growth Rate was 13.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Tempest Therapeutics's EBIT per Share or its related term are showing as below:

TPST' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: 13.4 Med: 13.4 Max: 13.4
Current: 13.4

During the past 4 years, the highest 3-Year average EBIT per Share Growth Rate of Tempest Therapeutics was 13.40% per year. The lowest was 13.40% per year. And the median was 13.40% per year.

TPST's 3-Year EBIT Growth Rate is ranked better than
63.59% of 1299 companies
in the Biotechnology industry
Industry Median: 3.4 vs TPST: 13.40

Tempest Therapeutics's EBIT for the three months ended in Mar. 2024 was $-7.54 Mil.

Tempest Therapeutics EBIT per Share Historical Data

The historical data trend for Tempest Therapeutics's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tempest Therapeutics EBIT per Share Chart

Tempest Therapeutics Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

EBIT per Share

-2.90

-7.13

-2.95

-1.82

Tempest Therapeutics Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EBIT per Share	Get a 7-Day Free Trial											-0.53	-0.51	-0.45	-0.37	-0.34

Tempest Therapeutics EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Tempest Therapeutics's EBIT per Share for the fiscal year that ended in Dec. 2023 is calculated as

	EBIT per Share		(A: Dec. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-28.042	/	15.416
=	-1.82

Tempest Therapeutics's EBIT per Share for the quarter that ended in Mar. 2024 is calculated as

	EBIT per Share		(Q: Mar. 2024 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-7.536	/	22.234
=	-0.34

EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.67

Tempest Therapeutics (NAS:TPST) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Tempest Therapeutics EBIT per Share Related Terms

Thank you for viewing the detailed overview of Tempest Therapeutics's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Tempest Therapeutics (Tempest Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tempest Therapeutics Inc (NAS:TPST) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

3OS:Germany 3OS:Germany

Address

2000 Sierra Point Parkway, Suite 400, Brisbane, CA, USA, 94005

Website

https://www.tempesttx.com

Tempest Therapeutics Inc is a clinical-stage biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity.

Executives

Justin Trojanowski	officer: Corporate Controller	C/O TEMPEST THERAPEUTICS, INC., 7000 SHORELINE COURT, SUITE 275, SOUTH SAN FRANCISCO CA 94080
Nicholas Maestas	officer: VP of Strategy and Finance	7000 SHORELINE COURT, SUITE 275, SOUTH SAN FRANCISCO CA 20005
Versant Venture Capital Vi, L.p.	10 percent owner	ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Versant Side Fund Iv, L.p.	10 percent owner	ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104
Versant Venture Capital Iv, L.p.	10 percent owner	ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104
Versant Ventures Iv, Llc	10 percent owner	ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104
Thomas Woiwode	director, 10 percent owner	ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Versant Ventures Vi Gp-gp, Llc	10 percent owner	ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104
Versant Ventures Vi Gp, L.p.	10 percent owner	ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104
Versant Vantage Ii, L.p.	10 percent owner	ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Versant Vantage Ii Gp-gp, Llc	10 percent owner	ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Versant Vantage Ii Gp, L.p.	10 percent owner	ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Thomas W. Dubensky	director, officer: President	C/O ADURO BIOTECH, INC., 740 HEINZ AVENUE, BERKELEY CA 94710
Samuel Whiting	officer: Chief Medical Officer	C/O TEMPEST THERAPEUTICS, INC., 7000 SHORELINE COURT, SUITE 275, SOUTH SAN FRANCISCO CA 94080
Rock Springs Capital Llc	10 percent owner	650 SOUTH EXETER STREET, SUITE 1070, BALTIMORE MD 21202